NCT05828745View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

February 18, 2025

Study Completion Date

February 18, 2025

Conditions

Chronic Hepatitis b

Interventions

DRUG

CB06-036

CB06-036 capsule

DRUG

Placebo

Placebo capsule

Trial Locations (2)

130000

First Hospital of Jilin University, Changchun

0622

"PCRN Trials Limited, trading as PCRN Auckland, Level 2, 2 Fred Thomas Drive, Takapuna, Auckland, 0622, New Zealand (hereinafter referred to as Institution)", Auckland

All Listed Sponsors

lead

Shanghai Zhimeng Biopharma, Inc.

INDUSTRY

NCT05828745 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B | Biotech Hunter | Biotech Hunter